Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

被引：0
|
作者：
Konstantin Huhn
Antonios Bayas
Sebastian Doerck
Benedikt Frank
Kathrin Gerbershagen
Kerstin Hellwig
Boris Kallmann
Christoph Kleinschnitz
Ingo Kleiter
De-Hyung Lee
Volker Limmroth
Mathias Mäurer
Sven Meuth
Peter Rieckmann
Tobias Ruck
Ralf Gold
Ralf A. Linker
机构：
[1] Friedrich-Alexander-University,Department of Neurology, University Hospital Erlangen
[2] Klinikum Augsburg,Department of Neurology
[3] Julius-Maximilians-University Würzburg,Department of Neurology
[4] University Hospital Essen,Department of Neurology
[5] Klinikum Köln-Merheim,Department of Neurology
[6] St. Josef-Hospital/Ruhr-University Bochum,Department of Neurology
[7] MS Center Bamberg,Department of Neurology
[8] Caritas Krankenhaus Bad Mergentheim,Department of Translational Neurology
[9] University Hospital Münster,Department of Neurology
[10] Julius-Spital Würzburg,undefined
[11] Marianne-Strauß-Klinik,undefined
[12] Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH,undefined
[13] Medical Park Klinik Loipl,undefined
来源：
Journal of Neurology | 2018年 / 265卷
关键词：
Alemtuzumab; Fingolimod; Multiple sclerosis; Disease-modifying treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1521 / 1527
页数：6
相关论文
共 50 条
  • [41] Analysis of First Line Therapy Criteria Responses in a Cohort of 1,300 Relapsing Remitting MS Patients
    Labauge, Pierre
    de Seze, Jerome
    Pelletier, Jean
    Dalliere, Clarisse Carra
    Aouinti, Safa
    Pinna, Frederic
    Bigaut, Kevin
    Maarouf, Adil
    Ayrignac, Xavier
    Picot, Marie Christinee
    NEUROLOGY, 2020, 94 (15)
  • [42] Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial
    Ozakbas, Serkan
    Turkoglu, Recai
    Tamam, Yusuf
    Terzi, Murat
    Taskapilioglu, Ozlem
    Yucesan, Canan
    Baser, Hatice Limoncu
    Gencer, Mehmet
    Akil, Esref
    Sen, Sedat
    Turan, Omer Faruk
    Sorgun, Mine Hayriye
    Yigit, Pinar
    Turkes, Nevin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 22 : 70 - 76
  • [43] Challenges in Undertaking a Multi-Center Prospective, Observational, Cohort Study in the Pediatric Oncology Population
    Nayiager, T.
    Halton, J.
    Brandao, L.
    Silva, M.
    Jardine, L.
    Chan, A.
    Thabane, L.
    Athale, U.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S497 - S498
  • [44] Efficacy of fingolimod in the 2nd line treatment of active relapsing-remitting multiple sclerosis: About a Tunisian cohort of 50 patients
    Saied, Zakaria
    Ghachem, Ichrak
    Nabli, Fatma
    Rachdi, Emine
    Jeridi, Cyrine
    Blel, Samir
    Ben Sassi, Samia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [45] Autonomic regulation of systemic inflammation in humans: A multi-center, blinded observational cohort study
    Ackland, Gareth L.
    Minto, Gary
    Clark, Martin
    Whittle, John
    Stephens, Robert C. M.
    Owen, Thomas
    Prabhu, Pradeep
    del Arroyo, Ana Gutierrez
    BRAIN BEHAVIOR AND IMMUNITY, 2018, 67 : 47 - 53
  • [46] Immunogenicity of alemtuzumab does not impact safety and efficacy in relapsing remitting multiple sclerosis patients in the CARE-MS I study
    Ziemssen, T.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K. W.
    Weiner, H. L.
    Palmer, J.
    Margolin, D. H.
    Richards, S.
    Sung, C.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 212 - 213
  • [47] No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis
    Wiendl, H.
    Brandes, D.
    Carraro, M.
    Comi, G.
    Mao-Draayer, Y.
    Izquierdo, G.
    Kim, H. -J.
    Meuth, S.
    Pardo, G.
    Sharrack, B.
    Tornatore, C.
    Ziemssen, T.
    Jacobs, A.
    Chung, L.
    Daizadeh, N.
    Van Wijmeersch, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 261 - 262
  • [48] MULTI-CENTER OBSERVATIONAL STUDY OF PERSONALITY AND IMPULSE CONTROL DISORDERS IN JAPANESE PATIENTS WITH PARKINSON'S DISEASE
    Shinoda, T.
    Nakashita, S.
    Hamada, M.
    Hirono, K.
    Ito, M.
    Kashihara, K.
    Miyagi, T.
    Namihira, Y.
    Tokashiki, T.
    Nakashima, K.
    Maeda, T.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E68 - E68
  • [49] Multi-center observational study of personality and impulse control disorders in Japanese patients with Parkinson's disease
    Shinoda, T.
    Nakashita, S.
    Hamada, M.
    Nakashima, K.
    Hirono, K.
    Ito, M.
    Kashihara, K.
    Miyagi, T.
    Namihira, Y.
    Tokashiki, T.
    Maeda, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 736 - 736
  • [50] A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab
    Raeuber, Saskia
    Pawlitzki, Marc
    Korsen, Melanie
    Kullmann, Jennifer S.
    Thoene, Daniela
    Pfeuffer, Steffen
    Rolfes, Leoni
    Nelke, Christopher
    Melzer, Nico
    Ruck, Tobias
    Meuth, Sven G.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
12345